Background: It is well known that mammographic screening reduces breast cancer mortality. One possible explanation for this effect is that screening makes it possible to detect smaller breast cancers with fewer involved nodes, but another hypothesis is that some screening-detected tumors are in a pathologically and biologically different phase of evolution from those that are detected clinically. The aim of the present study was to compare the biological, pathological and clinical characteristics of symptomatic vs. asymptomatic breast cancers.
Introduction
It is well known that mammographic screening in asymptomatic women aged 50-69 years reduces breast cancer mortality [1] [2] [3] [4] [5] [6] [7] because it allows the discovery of cancer at an early and still curable stage. One possible explanation of this effect is that screening allows the detection of smaller breast cancers with fewer involved nodes, but another hypothesis is that some of screeningdetected tumors are in a pathologically different phase of evolution from those detected clinically: i.e., at an earlier stage of evolution. This suggests that the natural history of breast cancer involves both tumor growth and biological progression towards a more aggressive status and, if this is true, a tumor diagnosed at an earlier stage should have a better intrinsic prognostic future than one diagnosed later. The key problem that emerges is the need to study screened versus non-screened tumors in terms of the pathological and biological markers of aggressiveness.
Many markers of different prognoses have been proposed in breast cancer. The classical pathological markers are size, axillary nodal involvement and grading; the preferred biological markers are those that can be evaluated by means of immunohistochemistry because they are easy to perform, reproducible and also allow morphological distribution to be studied. Estrogen and progesterone receptor negativity [8] [9] [10] , a high degree of proliferative activity determined using the Ki-67 monoclonal antibody [11] and, more recently, c-erbB-2 protein over-expression [12] [13] [14] have all been proposed as markers of more aggressive behaviour.
In order to contribute towards clarifying this problem, we compared the pathological and biological characteristics of infiltrating operable breast cancers in a series of 1916 symptomatic or asymptomatic patients.
Patients and methods

Patients
The study involved 1916 consecutive patients with invasive operable breast cancer, who attended the Universitary and Civic Hospitals of Verona between January 1992 and December 1998. Before surgery, all of the patients underwent mammography and an ultrasound scan, at least one of which was positive in all cases.
No organized public screening program was active in Verona during this period, but 33.1% of these patients underwent mammography and ultrasonography in the absence of any subjective symptom because of their awareness of breast cancer; they had not undergone senological examination on a regular basis (as in a screening program) and, for many of them, this was the first time. The other patients were examined because of the presence of a breast lump. During their first visit to the Department of Medical Oncology, the patients were asked why they had undergone the imaging examination: those who had done so because of the presence of discomfort or a lump in their breast were defined symptomatic (group A) and those without any subjective symptom were defined asymptomatic (group B); all of the answers were checked at the subsequent visit.
All of the patients were assigned a pathological TNM stage according to the Union International Contre le Cancer (U.I.C.C.) criteria. The pathological size (pT) and diameter of the tumors (measured in millimetres) were recorded, as was their grading and the number of positive axillary nodes (pN). Fifty-three tumors were excluded from this analysis because multicentncity made it impossible to define their diameters.
The tumor samples obtained at the time of primary surgery underwent initial pathological examination, and portions of each were frozen in liquid nitrogen and stored at -70 °C until the time of biological characterization. Estrogen (ER) and progesterone receptor (PgR) status were determined by means of immunohistochemistry (ICH), with the tumors being considered ER or PgR positive if more than 10% of the cells were stained. We decided to use the ICH method of receptor characterization because, in a previous study [10] , we demonstrated that there is a very good correlation between this and the biochemical method; however, given the controversy in the literature regarding the cut-off point for these receptors, we considered ER and PgR status as a continuous variable ranging from 0%-100% of positive stained cells/total.
Immunohistochemical staining for replicative cell fractions was performed using the Ki-67 monoclonal antibody (DAKO-PC) as previously described [11] and, once again, Ki-67 was considered as a continuous variable. C-erbB-2 levels were determined by means of ICH using the DAKO-PC monoclonal antibody, and the tumors were considered positive if at least one cell was stained.
Statistical methods
The associations between each of the considered variables and the probability of having a symptomatic diagnosis were evaluated using logistic regression analysis [IS] . Significance was tested using the likelihood ratio statistic and a significance level of 0.05. Age, tumor size, ER, PgR and Ki-67 were analyzed as continuous variables; the other variables were treated as categorical (c-erbB-2: negative/positive; grading: 1, 2, 3; pT: 1, 2, 3; nodal status: negative, 1-3 positive nodes, 4 or more positive nodes).
Results
Group A consisted of 1247 patients (66.9%) and group B of 616 (33.1%). Table 1 (Table 1) .
In order to compare differences in the prevalence of group A women in relation to the considered variables (i.e., the probability of having a symptomatic diagnosis), logistic regression analysis was used with the presence of a symptomatic diagnosis as the dependent variable ( Table 2 ). All of the variables were significantly associated with the modality of diagnosis, thus confirming the previous findings. Tumor diameter was the most significant, with a chi-square value of 192, but a similar value (117) was also found for pT. Among the other variables, Ki-67 was the most significant, followed by N, grading, age, PgR, c-erbB-2 and ER.
Since the most striking feature of women with an asymptomatic diagnosis is a smaller tumor size, an adjusted analysis was made in order to evaluate the effect of the other considered variables after having taken tumor diameter into account. The results are shown in Table 3 . The significance of each variable was always lower after adjusting for tumor size, but all of them remained significantly associated with the modality of diagnosis except ER (P -0.343), PgR (P -0.147) and c-erbB-2 (P -0.06): the group A symptomatic patients were mainly characterized by larger tumors but, when compared with group B patients whose tumor diameter was the same, they were still older and had higher Ki-67 values, more involved nodes and a higher grading. No significant interaction with tumor size was found. These results did not change after simultaneous adjustment for tumour size and age (Table 4) . A final analysis was made by simultaneously considering tumor size, age, ER, Ki-67 and N (PgR, grading and c-erb were excluded from this analysis since there were many missing data). Of these variables, only ER was not significantly associated with the probability of having a symptomatic diagnosis. When this analysis was repeated in the subgroup of patients whose grading status was also available, the same variables remained significant but grading was no longer associated with the modality of diagnosis (chi-square = 0.64 with 2 d.f.).
Discussion
Our study refers to a consecutive series of infiltrating breast cancer patients who underwent surgery after a positive ultrasound and/or mammography examination. The patients in group A were symptomatic (i.e., they noticed a mass at self-palpation or experienced breast discomfort), whereas those in group B underwent the imaging examinations as a check without experiencing any symptoms. They were different from a screened population because they also underwent clinical and ultrasound examinations, and none of the examinations was done on a regular basis. However, the aim of this study was not to evaluate the biological characteristics of screened versus unscreened cancers, but to investigate whether there were any differences in the biological characteristics of symptomatic and asymptomatic cancers.
Age at diagnosis was different in the two groups, with group A patients being generally older than those in group B. However, the cumulative distribution shown in Figure 1 seems to indicate a bimodal age pattern: the proportion of asymptomatic patients was greater up to the age of 52 years but, after this age, there was a clear excess of symptomatic patients. This may be because younger women are more health conscious.
The patients in group A had larger tumors and greater nodal involvement, but this was expected because many authors [16] [17] [18] [19] [20] [21] [22] have already shown that symptomatic tumors are larger and involve more nodes than screened tumors.
The investigation of the other parameters led to some interesting results. The cancers in group A had a more aggressive and worse prognostic phenotype, with a higher percentage of ER and PgR negativity, a higher proliferative index, a higher grading and a higher percentage of c-erbB-2 positivity.
Many studies comparing screened and symptomatic cases have found similar associations in relation to ER [17, 23] , although others have not [16, 24] , and some have not found any association with progesterone receptors [24] . Rajakariar et al. [17] and Moezzi et al. [24] have found an association with Ki-67, and Klemi et al. [25] , Cowan et al. [16] , Tweedie et al. [26] , Moezzi et al. [24] and Burrel et al. [22] with grading; Gibbs [27] found an association with size but not with the modality of diagnosis. A positive significant association with c-erbB-2 was found by Rajakariar et al. [17] , but Soomro et al. [28] found only a trend for c-erbB-2 negativity in impalpable versus palpable tumors in a screened population. Cowan et al. [16] and Tweedie et al. [26] did not find any difference in the frequency of c-erbB-2 positivity between screened and unscreened, or palpable and occult tumors, respectively.
Some authors have failed to find any association between the modality of diagnosis and the markers of aggressiveness [16, 27, 29] , and therefore concluded that the favourable characteristics of screen-detected cancers are almost always only due to the effect of length bias on biological factors [29] : i.e., the effect of a smaller diameter. According to Moezzi et al. [24] , breast cancers found by screening are small and so, although already invasive, have not yet undergone sufficient cell division cycles to induce the genetic changes that determine the phenotypic characteristics representing poor prognostic indicators.
On the contrary, many authors have demonstrated that the pathological and biological characteristics of screened breast cancers indicate a lower degree of malignancy [17, 18, 22, 24, 26] .
In an attempt to clarify this issue, we evaluated the effect of the considered variables after adjusting for tumor diameter. The results given in Table 3 show that the association between modality of diagnosis and nodal status, as well as that between modality of diagnosis and markers of aggressiveness such as grading and Ki-67, remained statistically significant after the adjustment, whereas the association with ER and PgR was no longer significant, and that with c-erbB-2 was of only bordeline significance. Similar results were obtained after age adjustment.
Our results partially agree with those of Klemy et al. [25] , who found an association between biological parameters (ER, PgR, grading) and the modality of diagnosis even after adjustment for primary tumor size, and seem to indicate that the difference between symptomatic and asymptomatic breast cancers are not only due to the effect of size, but probably also to a different biological phenotype that makes asymptomatic tumors less aggressive than their symptomatic counterparts.
Our results are also in agreement with the new breast cancer hypothesis formulated by Hellman, according to whom breast cancer is a spectrum of diseases with different capacities for growth and metastasis, and the increased tumor volume necessary for clinical detection provides more clonogens available for metastasis and cause further progression of the malignant phenotype [30] [31] [32] .
If this is the case, screening allows cancers to be found at an earlier and probably less malignant stage of development, when they may not have achieved metastatic potential (as judged by their favourable pathological and biological features). Tumor progression occurs late in this preclinical phase, with a proportion of impalpable carcinomas undergoing dedifferentiation with increasing size, and thus becoming more invasive and metastatic.
